To cite this paper use one of the standards below:
Despite numerous drugs for treatment of tuberculosis (TB) infections being available it remains a devastating disease. New drugs are desperately needed to shorten TB treatment to improve patient compliance and drug resistance. One promising new target for TB treatment is caseinolytic protease (ClpP1P2). Based on the similarity of ClpP1P2 to the human proteasome, we propose using known proteasome inhibitors as starting points for a structurally enabled ClpP1P2 hit-to-lead campaign. Importantly, our efforts will focus on proteasome inhibitors identified as active in whole-cell Mycobacterium tuberculosis (Mtb) assays. Docking of these cell-active compounds into the Mtb ClpP1P2 active site has identify putative binding modes which will aid the design of more potent inhibitors as well as inhibitors with suitable selectivity for Mtb ClpP1P2 over mammalian cells. In this work a literature Mtb ClpP1P2 enzymatic assay was used to determine on-target activity of the synthesized inhibitors and to correlate with whole-cell Mtb activity.
With nearly 200,000 papers published, Galoá empowers scholars to share and discover cutting-edge research through our streamlined and accessible academic publishing platform.
Learn more about our products:
This proceedings is identified by a DOI , for use in citations or bibliographic references. Attention: this is not a DOI for the paper and as such cannot be used in Lattes to identify a particular work.
Check the link "How to cite" in the paper's page, to see how to properly cite the paper